D. E. Shaw & Co., Inc. Argenx Se Call Options Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
Call Options
2 transactions
Others Institutions Holding ARGX
# of Institutions
356Shares Held
31.3MCall Options Held
212KPut Options Held
210K-
Price T Rowe Associates Inc Baltimore, MD5.5MShares$2.4 Billion0.27% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.19MShares$1.39 Billion1.93% of portfolio
-
Janus Henderson Group PLC London, X02.22MShares$965 Million0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.12MShares$921 Million0.51% of portfolio
-
Capital World Investors Los Angeles, CA1.86MShares$812 Million0.13% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $24.1B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...